Marker Therapeutics Future Growth
Future criteria checks 2/6
Marker Therapeutics's earnings are forecast to decline at 38.9% per annum while its annual revenue is expected to grow at 70.7% per year. EPS is expected to decline by 10.4% per annum.
Key information
-38.9%
Earnings growth rate
-10.4%
EPS growth rate
| Biotechs earnings growth | 42.2% |
| Revenue growth rate | 70.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2 | -67 | N/A | N/A | 1 |
| 12/31/2025 | 4 | -44 | N/A | N/A | 1 |
| 12/31/2024 | 5 | -11 | N/A | N/A | 1 |
| 9/30/2024 | 5 | -10 | -9 | -9 | N/A |
| 6/30/2024 | 4 | -10 | -11 | -11 | N/A |
| 3/31/2024 | 3 | -12 | -14 | -14 | N/A |
| 12/31/2023 | 3 | -14 | -16 | -16 | N/A |
| 9/30/2023 | 3 | -14 | -20 | -20 | N/A |
| 6/30/2023 | 4 | -17 | -27 | -27 | N/A |
| 3/31/2023 | 4 | -14 | -18 | -21 | N/A |
| 12/31/2022 | 4 | -20 | -27 | -27 | N/A |
| 9/30/2022 | 4 | -26 | -26 | -26 | N/A |
| 6/30/2022 | 3 | -33 | -27 | -25 | N/A |
| 3/31/2022 | 2 | -43 | -36 | -31 | N/A |
| 12/31/2021 | 1 | -42 | -30 | -27 | N/A |
| 9/30/2021 | N/A | -41 | -35 | -28 | N/A |
| 6/30/2021 | N/A | -36 | -34 | -27 | N/A |
| 3/31/2021 | 0 | -31 | -35 | -24 | N/A |
| 12/31/2020 | 0 | -29 | -29 | -20 | N/A |
| 9/30/2020 | 1 | -25 | -24 | -19 | N/A |
| 6/30/2020 | 1 | -23 | -23 | -19 | N/A |
| 3/31/2020 | 0 | -23 | -19 | -19 | N/A |
| 12/31/2019 | 0 | -21 | -19 | -18 | N/A |
| 9/30/2019 | N/A | -152 | -20 | -20 | N/A |
| 6/30/2019 | N/A | -151 | -18 | -18 | N/A |
| 3/31/2019 | 0 | -150 | -16 | -16 | N/A |
| 12/31/2018 | 0 | -148 | -15 | -14 | N/A |
| 9/30/2018 | 0 | -15 | -11 | -11 | N/A |
| 6/30/2018 | 0 | -15 | N/A | -9 | N/A |
| 3/31/2018 | 0 | -12 | N/A | -9 | N/A |
| 12/31/2017 | 0 | -11 | N/A | -8 | N/A |
| 9/30/2017 | 0 | -10 | N/A | -8 | N/A |
| 6/30/2017 | N/A | -8 | N/A | -8 | N/A |
| 3/31/2017 | N/A | 0 | N/A | -8 | N/A |
| 12/31/2016 | N/A | -2 | N/A | -7 | N/A |
| 9/30/2016 | N/A | -3 | N/A | -6 | N/A |
| 6/30/2016 | N/A | 28 | N/A | -5 | N/A |
| 3/31/2016 | N/A | -38 | N/A | -4 | N/A |
| 12/31/2015 | N/A | -34 | N/A | -4 | N/A |
| 9/30/2015 | N/A | -33 | N/A | -4 | N/A |
| 6/30/2015 | N/A | -63 | N/A | -3 | N/A |
| 3/31/2015 | N/A | -2 | N/A | -3 | N/A |
| 12/31/2014 | N/A | -31 | N/A | -2 | N/A |
| 9/30/2014 | N/A | -34 | N/A | -1 | N/A |
| 6/30/2014 | N/A | -33 | N/A | -1 | N/A |
| 3/31/2014 | N/A | -35 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GX1 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GX1 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GX1 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GX1's revenue (70.7% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: GX1's revenue (70.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GX1's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 03:31 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Marker Therapeutics, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Yun Zhong | Janney Montgomery Scott LLC |
| Aydin Huseynov | Ladenburg Thalmann & Company |